Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes.
The effect of recombinant GH on strength, body composition and endocrine parameters in power athletes was investigated in a controlled study. Twenty-two healthy, non-obese males (age 23.4 +/- 0.5 years; ideal body weight 122 +/- 3.1%, body fat 10.1 +/- 1.0%; mean +/- SEM) were included. Probands were assigned in a double-blind manner to either GH treatment (0.09U (kg BW)-1 day-1 sc) or placebo for a period of six weeks. To exclude concurrent treatment with androgenic-anabolic steroids urine specimens were tested at regular intervals for these substances. Serum was assayed for GH, IGF-I, IGF-binding proteins, insulin and thyroxine before the onset of the study and at two-weekly intervals thereafter. Maximal voluntary strength of the biceps and quadriceps muscles was measured on a strength training apparatus. Fat mass and lean body mass were derived from measurements of skinfolds at ten sites with a caliper. For final evaluation only data of those 8 and 10 subjects in the two groups who completed the study were analyzed. GH, IGF-I and IGF-binding protein were in the normal range before therapy and increased significantly in the GH-treated group. Fasting insulin concentrations increased insignificantly and thyroxine levels decreased significantly in the GH-treated probands. There was no effect of GH treatment on maximal strength during concentric contraction of the biceps and quadriceps muscles. Body weight and body fat were not changed significantly during treatment. We conclude that the anabolic, lipolytic effect of GH therapy in adults depends on the degree of fat mass and GH deficiency.(ABSTRACT TRUNCATED AT 250 WORDS)
Deyssig
R
R
Department of Paediatrics, University of Vienna, Austria.
Frisch
H
H
Blum
W F
WF
Waldhör
T
T
D000328:Adult; D001823:Body Composition / Q000187:drug effects*; D015992:Body Mass Index; D002352:Carrier Proteins / Q000097:blood; D004311:Double-Blind Method; D013006:Growth Hormone / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007335:Insulin-Like Growth Factor II / Q000032:analysis; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000502:physiology; D010352:Patient Dropouts; D010807:Physical Endurance / Q000187:drug effects*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000494:pharmacology; D013177:Sports; D013963:Thyroid Hormones / Q000097:blood
D002352:Carrier Proteins; D006131:Growth Inhibitors; D006728:Hormones; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D013963:Thyroid Hormones; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone